APO Research
Talk to an analyst

APO RESEARCH · REPORT

Imatinib Mesylate API

Compare research editions
View pricing & licenses

Selected research

Industry Research

Imatinib Mesylate API Industry Research Report 2026

23 December 2025137 pages

Choose your research edition.

Industry ResearchImatinib Mesylate API Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Imatinib Mesylate API Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Imatinib Mesylate API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Imatinib Mesylate API Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Imatinib Mesylate API Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Imatinib Mesylate API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Imatinib Mesylate API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Imatinib Mesylate API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Imatinib Mesylate API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Imatinib Mesylate API include Zhejiang Jiuzhou Pharmaceutical Co Ltd, Sun Pharma, Shanghai Yuanye Bio-Technology, Shandong Anxin Pharmaceutical Co Ltd, Mylan, Zydus Lifesciences Ltd, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd and Shilpa Pharma Lifesciences Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Imatinib Mesylate API market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Imatinib Mesylate API Market by Company

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Sun Pharma

Shanghai Yuanye Bio-Technology

Shandong Anxin Pharmaceutical Co Ltd

Mylan

Zydus Lifesciences Ltd

Zydus Lifesciences

Sun Pharmaceutical Industries Ltd

Shilpa Pharma Lifesciences Ltd

Natco Pharma Ltd

Msn Laboratories Private Ltd

Laurus Labs Ltd

Intas Pharmaceuticals Ltd

Hetero Labs Ltd

Dr. Reddy’s

Cipla Ltd

Aurobindo Pharma Ltd

Acebright India Pharma Private Ltd

Imatinib Mesylate API Segment by Type

Purity ≥ 98%

Purity < 98%

Imatinib Mesylate API Segment by Application

Chronic Myeloid Leukemia (CML)

Gastrointestinal Stromal Tumor (GIST)

Others

Imatinib Mesylate API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Imatinib Mesylate API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Imatinib Mesylate API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Imatinib Mesylate API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Imatinib Mesylate API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Imatinib Mesylate API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Imatinib Mesylate API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Imatinib Mesylate API Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Imatinib Mesylate API Sales (kg) of Manufacturers (2021-2026) Table 7. Global Imatinib Mesylate API Sales Market Share by Manufacturers (2021-2026) Table 8. Global Imatinib Mesylate API Revenue of Manufacturers (2021-2026) Table 9. Global Imatinib Mesylate API Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Imatinib Mesylate API Average Price (USD/g) of Manufacturers (2021-2026) Table 11. Global Imatinib Mesylate API Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Imatinib Mesylate API, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Imatinib Mesylate API, Product Type & Application Table 14. Global Imatinib Mesylate API Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Imatinib Mesylate API by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zhejiang Jiuzhou Pharmaceutical Co Ltd Company Information Table 19. Zhejiang Jiuzhou Pharmaceutical Co Ltd Business Overview Table 20. Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 21. Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio Table 22. Zhejiang Jiuzhou Pharmaceutical Co Ltd Recent Developments Table 23. Sun Pharma Company Information Table 24. Sun Pharma Business Overview Table 25. Sun Pharma Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 26. Sun Pharma Imatinib Mesylate API Product Portfolio Table 27. Sun Pharma Recent Developments Table 28. Shanghai Yuanye Bio-Technology Company Information Table 29. Shanghai Yuanye Bio-Technology Business Overview Table 30. Shanghai Yuanye Bio-Technology Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 31. Shanghai Yuanye Bio-Technology Imatinib Mesylate API Product Portfolio Table 32. Shanghai Yuanye Bio-Technology Recent Developments Table 33. Shandong Anxin Pharmaceutical Co Ltd Company Information Table 34. Shandong Anxin Pharmaceutical Co Ltd Business Overview Table 35. Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 36. Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio Table 37. Shandong Anxin Pharmaceutical Co Ltd Recent Developments Table 38. Mylan Company Information Table 39. Mylan Business Overview Table 40. Mylan Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 41. Mylan Imatinib Mesylate API Product Portfolio Table 42. Mylan Recent Developments Table 43. Zydus Lifesciences Ltd Company Information Table 44. Zydus Lifesciences Ltd Business Overview Table 45. Zydus Lifesciences Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 46. Zydus Lifesciences Ltd Imatinib Mesylate API Product Portfolio Table 47. Zydus Lifesciences Ltd Recent Developments Table 48. Zydus Lifesciences Company Information Table 49. Zydus Lifesciences Business Overview Table 50. Zydus Lifesciences Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 51. Zydus Lifesciences Imatinib Mesylate API Product Portfolio Table 52. Zydus Lifesciences Recent Developments Table 53. Sun Pharmaceutical Industries Ltd Company Information Table 54. Sun Pharmaceutical Industries Ltd Business Overview Table 55. Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 56. Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio Table 57. Sun Pharmaceutical Industries Ltd Recent Developments Table 58. Shilpa Pharma Lifesciences Ltd Company Information Table 59. Shilpa Pharma Lifesciences Ltd Business Overview Table 60. Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 61. Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Product Portfolio Table 62. Shilpa Pharma Lifesciences Ltd Recent Developments Table 63. Natco Pharma Ltd Company Information Table 64. Natco Pharma Ltd Business Overview Table 65. Natco Pharma Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 66. Natco Pharma Ltd Imatinib Mesylate API Product Portfolio Table 67. Natco Pharma Ltd Recent Developments Table 68. Msn Laboratories Private Ltd Company Information Table 69. Msn Laboratories Private Ltd Business Overview Table 70. Msn Laboratories Private Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 71. Msn Laboratories Private Ltd Imatinib Mesylate API Product Portfolio Table 72. Msn Laboratories Private Ltd Recent Developments Table 73. Laurus Labs Ltd Company Information Table 74. Laurus Labs Ltd Business Overview Table 75. Laurus Labs Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 76. Laurus Labs Ltd Imatinib Mesylate API Product Portfolio Table 77. Laurus Labs Ltd Recent Developments Table 78. Intas Pharmaceuticals Ltd Company Information Table 79. Intas Pharmaceuticals Ltd Business Overview Table 80. Intas Pharmaceuticals Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 81. Intas Pharmaceuticals Ltd Imatinib Mesylate API Product Portfolio Table 82. Intas Pharmaceuticals Ltd Recent Developments Table 83. Hetero Labs Ltd Company Information Table 84. Hetero Labs Ltd Business Overview Table 85. Hetero Labs Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 86. Hetero Labs Ltd Imatinib Mesylate API Product Portfolio Table 87. Hetero Labs Ltd Recent Developments Table 88. Dr. Reddy’s Company Information Table 89. Dr. Reddy’s Business Overview Table 90. Dr. Reddy’s Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 91. Dr. Reddy’s Imatinib Mesylate API Product Portfolio Table 92. Dr. Reddy’s Recent Developments Table 93. Cipla Ltd Company Information Table 94. Cipla Ltd Business Overview Table 95. Cipla Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 96. Cipla Ltd Imatinib Mesylate API Product Portfolio Table 97. Cipla Ltd Recent Developments Table 98. Aurobindo Pharma Ltd Company Information Table 99. Aurobindo Pharma Ltd Business Overview Table 100. Aurobindo Pharma Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 101. Aurobindo Pharma Ltd Imatinib Mesylate API Product Portfolio Table 102. Aurobindo Pharma Ltd Recent Developments Table 103. Acebright India Pharma Private Ltd Company Information Table 104. Acebright India Pharma Private Ltd Business Overview Table 105. Acebright India Pharma Private Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 106. Acebright India Pharma Private Ltd Imatinib Mesylate API Product Portfolio Table 107. Acebright India Pharma Private Ltd Recent Developments Table 108. Global Imatinib Mesylate API Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Imatinib Mesylate API Sales by Region (2021-2026) & (kg) Table 110. Global Imatinib Mesylate API Sales Market Share by Region (2021-2026) Table 111. Global Imatinib Mesylate API Sales by Region (2027-2032) & (kg) Table 112. Global Imatinib Mesylate API Sales Market Share by Region (2027-2032) Table 113. Global Imatinib Mesylate API Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Imatinib Mesylate API Revenue Market Share by Region (2021-2026) Table 115. Global Imatinib Mesylate API Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Imatinib Mesylate API Revenue Market Share by Region (2027-2032) Table 117. North America Imatinib Mesylate API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 119. North America Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 120. North America Imatinib Mesylate API Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Imatinib Mesylate API Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Imatinib Mesylate API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 124. Europe Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 125. Europe Imatinib Mesylate API Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Imatinib Mesylate API Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Imatinib Mesylate API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 129. Asia Pacific Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 130. Asia Pacific Imatinib Mesylate API Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Imatinib Mesylate API Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Imatinib Mesylate API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 134. South America Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 135. South America Imatinib Mesylate API Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Imatinib Mesylate API Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Imatinib Mesylate API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 139. Middle East and Africa Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 140. Middle East and Africa Imatinib Mesylate API Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Imatinib Mesylate API Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Imatinib Mesylate API Sales by Type (2021-2026) & (kg) Table 143. Global Imatinib Mesylate API Sales by Type (2027-2032) & (kg) Table 144. Global Imatinib Mesylate API Sales Market Share by Type (2021-2026) Table 145. Global Imatinib Mesylate API Sales Market Share by Type (2027-2032) Table 146. Global Imatinib Mesylate API Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Imatinib Mesylate API Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Imatinib Mesylate API Revenue Market Share by Type (2021-2026) Table 149. Global Imatinib Mesylate API Revenue Market Share by Type (2027-2032) Table 150. Global Imatinib Mesylate API Price by Type (2021-2026) & (USD/g) Table 151. Global Imatinib Mesylate API Price by Type (2027-2032) & (USD/g) Table 152. Global Imatinib Mesylate API Sales by Application (2021-2026) & (kg) Table 153. Global Imatinib Mesylate API Sales by Application (2027-2032) & (kg) Table 154. Global Imatinib Mesylate API Sales Market Share by Application (2021-2026) Table 155. Global Imatinib Mesylate API Sales Market Share by Application (2027-2032) Table 156. Global Imatinib Mesylate API Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Imatinib Mesylate API Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Imatinib Mesylate API Revenue Market Share by Application (2021-2026) Table 159. Global Imatinib Mesylate API Revenue Market Share by Application (2027-2032) Table 160. Global Imatinib Mesylate API Price by Application (2021-2026) & (USD/g) Table 161. Global Imatinib Mesylate API Price by Application (2027-2032) & (USD/g) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Imatinib Mesylate API Distributors List Table 165. Imatinib Mesylate API Customers List Table 166. Imatinib Mesylate API Industry Trends Table 167. Imatinib Mesylate API Industry Drivers Table 168. Imatinib Mesylate API Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Imatinib Mesylate API Product Image Figure 5. Global Imatinib Mesylate API Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Imatinib Mesylate API Market Size (2021-2032) & (US$ Million) Figure 7. Global Imatinib Mesylate API Sales (2021-2032) & (kg) Figure 8. Global Imatinib Mesylate API Average Price (USD/g) & (2021-2032) Figure 9. Purity ≥ 98% Product Image Figure 10. Purity < 98% Product Image Figure 11. Chronic Myeloid Leukemia (CML) Product Image Figure 12. Gastrointestinal Stromal Tumor (GIST) Product Image Figure 13. Others Product Image Figure 14. Global Imatinib Mesylate API Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Imatinib Mesylate API, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Imatinib Mesylate API Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Imatinib Mesylate API Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Imatinib Mesylate API Sales by Region in 2025 Figure 20. Global Imatinib Mesylate API Revenue by Region in 2025 Figure 21. North America Imatinib Mesylate API Market Size by Country in 2025 Figure 22. North America Imatinib Mesylate API Sales Market Share by Country (2021-2032) Figure 23. North America Imatinib Mesylate API Revenue Market Share by Country (2021-2032) Figure 24. United States Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Imatinib Mesylate API Market Size by Country in 2025 Figure 28. Europe Imatinib Mesylate API Sales Market Share by Country (2021-2032) Figure 29. Europe Imatinib Mesylate API Revenue Market Share by Country (2021-2032) Figure 30. Germany Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Imatinib Mesylate API Market Size by Country in 2025 Figure 41. Asia Pacific Imatinib Mesylate API Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Imatinib Mesylate API Revenue Market Share by Country (2021-2032) Figure 43. China Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Imatinib Mesylate API Market Size by Country in 2025 Figure 52. South America Imatinib Mesylate API Sales Market Share by Country (2021-2032) Figure 53. South America Imatinib Mesylate API Revenue Market Share by Country (2021-2032) Figure 54. Brazil Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Imatinib Mesylate API Market Size by Country in 2025 Figure 58. Middle East and Africa Imatinib Mesylate API Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Imatinib Mesylate API Revenue Market Share by Country (2021-2032) Figure 60. Egypt Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Imatinib Mesylate API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Imatinib Mesylate API Sales Market Share by Type (2021-2032) Figure 66. Global Imatinib Mesylate API Revenue Market Share by Type (2021-2032) Figure 67. Global Imatinib Mesylate API Price (USD/g) by Type (2021-2032) Figure 68. Global Imatinib Mesylate API Sales Market Share by Application (2021-2032) Figure 69. Global Imatinib Mesylate API Revenue Market Share by Application (2021-2032) Figure 70. Global Imatinib Mesylate API Price (USD/g) by Application (2021-2032) Figure 71. Imatinib Mesylate API Value Chain Figure 72. Imatinib Mesylate API Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Imatinib Mesylate API Industry Opportunities and Challenges

Scope & coverage.

Types
  • Purity ≥ 98%
  • Purity < 98%
Applications
  • Chronic Myeloid Leukemia (CML)
  • Gastrointestinal Stromal Tumor (GIST)
  • Others
Companies covered
  • Zhejiang Jiuzhou Pharmaceutical Co Ltd
  • Sun Pharma
  • Shanghai Yuanye Bio-Technology
  • Shandong Anxin Pharmaceutical Co Ltd
  • Mylan
  • Zydus Lifesciences Ltd
  • Zydus Lifesciences
  • Sun Pharmaceutical Industries Ltd
  • Shilpa Pharma Lifesciences Ltd
  • Natco Pharma Ltd
  • Msn Laboratories Private Ltd
  • Laurus Labs Ltd
  • Intas Pharmaceuticals Ltd
  • Hetero Labs Ltd
  • Dr. Reddy’s
  • Cipla Ltd
  • Aurobindo Pharma Ltd
  • Acebright India Pharma Private Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Imatinib Mesylate API Market Size (2021-2032)
  4. 2.2.2 Global Imatinib Mesylate API Sales (2021-2032)
  5. 2.2.3 Global Imatinib Mesylate API Market Average Price (2021-2032)
  6. 2.3 Imatinib Mesylate API by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Purity ≥ 98%
  9. 2.3.3 Purity < 98%
  10. 2.4 Imatinib Mesylate API by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Chronic Myeloid Leukemia (CML)
  13. 2.4.3 Gastrointestinal Stromal Tumor (GIST)
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Imatinib Mesylate API Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Imatinib Mesylate API Sales (kg) of Manufacturers (2021-2026)
  3. 3.3 Global Imatinib Mesylate API Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Imatinib Mesylate API Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Imatinib Mesylate API Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Imatinib Mesylate API, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Imatinib Mesylate API, Product Type & Application
  8. 3.8 Global Manufacturers of Imatinib Mesylate API, Established Date
  9. 3.9 Global Imatinib Mesylate API Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zhejiang Jiuzhou Pharmaceutical Co Ltd
  2. 4.1.1 Zhejiang Jiuzhou Pharmaceutical Co Ltd Company Information
  3. 4.1.2 Zhejiang Jiuzhou Pharmaceutical Co Ltd Business Overview
  4. 4.1.3 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
  6. 4.1.5 Zhejiang Jiuzhou Pharmaceutical Co Ltd Recent Developments
  7. 4.2 Sun Pharma
  8. 4.2.1 Sun Pharma Company Information
  9. 4.2.2 Sun Pharma Business Overview
  10. 4.2.3 Sun Pharma Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sun Pharma Imatinib Mesylate API Product Portfolio
  12. 4.2.5 Sun Pharma Recent Developments
  13. 4.3 Shanghai Yuanye Bio-Technology
  14. 4.3.1 Shanghai Yuanye Bio-Technology Company Information
  15. 4.3.2 Shanghai Yuanye Bio-Technology Business Overview
  16. 4.3.3 Shanghai Yuanye Bio-Technology Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Shanghai Yuanye Bio-Technology Imatinib Mesylate API Product Portfolio
  18. 4.3.5 Shanghai Yuanye Bio-Technology Recent Developments
  19. 4.4 Shandong Anxin Pharmaceutical Co Ltd
  20. 4.4.1 Shandong Anxin Pharmaceutical Co Ltd Company Information
  21. 4.4.2 Shandong Anxin Pharmaceutical Co Ltd Business Overview
  22. 4.4.3 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
  24. 4.4.5 Shandong Anxin Pharmaceutical Co Ltd Recent Developments
  25. 4.5 Mylan
  26. 4.5.1 Mylan Company Information
  27. 4.5.2 Mylan Business Overview
  28. 4.5.3 Mylan Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mylan Imatinib Mesylate API Product Portfolio
  30. 4.5.5 Mylan Recent Developments
  31. 4.6 Zydus Lifesciences Ltd
  32. 4.6.1 Zydus Lifesciences Ltd Company Information
  33. 4.6.2 Zydus Lifesciences Ltd Business Overview
  34. 4.6.3 Zydus Lifesciences Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Zydus Lifesciences Ltd Imatinib Mesylate API Product Portfolio
  36. 4.6.5 Zydus Lifesciences Ltd Recent Developments
  37. 4.7 Zydus Lifesciences
  38. 4.7.1 Zydus Lifesciences Company Information
  39. 4.7.2 Zydus Lifesciences Business Overview
  40. 4.7.3 Zydus Lifesciences Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Zydus Lifesciences Imatinib Mesylate API Product Portfolio
  42. 4.7.5 Zydus Lifesciences Recent Developments
  43. 4.8 Sun Pharmaceutical Industries Ltd
  44. 4.8.1 Sun Pharmaceutical Industries Ltd Company Information
  45. 4.8.2 Sun Pharmaceutical Industries Ltd Business Overview
  46. 4.8.3 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio
  48. 4.8.5 Sun Pharmaceutical Industries Ltd Recent Developments
  49. 4.9 Shilpa Pharma Lifesciences Ltd
  50. 4.9.1 Shilpa Pharma Lifesciences Ltd Company Information
  51. 4.9.2 Shilpa Pharma Lifesciences Ltd Business Overview
  52. 4.9.3 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Product Portfolio
  54. 4.9.5 Shilpa Pharma Lifesciences Ltd Recent Developments
  55. 4.10 Natco Pharma Ltd
  56. 4.10.1 Natco Pharma Ltd Company Information
  57. 4.10.2 Natco Pharma Ltd Business Overview
  58. 4.10.3 Natco Pharma Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Natco Pharma Ltd Imatinib Mesylate API Product Portfolio
  60. 4.10.5 Natco Pharma Ltd Recent Developments
  61. 4.11 Msn Laboratories Private Ltd
  62. 4.11.1 Msn Laboratories Private Ltd Company Information
  63. 4.11.2 Msn Laboratories Private Ltd Business Overview
  64. 4.11.3 Msn Laboratories Private Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Msn Laboratories Private Ltd Imatinib Mesylate API Product Portfolio
  66. 4.11.5 Msn Laboratories Private Ltd Recent Developments
  67. 4.12 Laurus Labs Ltd
  68. 4.12.1 Laurus Labs Ltd Company Information
  69. 4.12.2 Laurus Labs Ltd Business Overview
  70. 4.12.3 Laurus Labs Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Laurus Labs Ltd Imatinib Mesylate API Product Portfolio
  72. 4.12.5 Laurus Labs Ltd Recent Developments
  73. 4.13 Intas Pharmaceuticals Ltd
  74. 4.13.1 Intas Pharmaceuticals Ltd Company Information
  75. 4.13.2 Intas Pharmaceuticals Ltd Business Overview
  76. 4.13.3 Intas Pharmaceuticals Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Intas Pharmaceuticals Ltd Imatinib Mesylate API Product Portfolio
  78. 4.13.5 Intas Pharmaceuticals Ltd Recent Developments
  79. 4.14 Hetero Labs Ltd
  80. 4.14.1 Hetero Labs Ltd Company Information
  81. 4.14.2 Hetero Labs Ltd Business Overview
  82. 4.14.3 Hetero Labs Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Hetero Labs Ltd Imatinib Mesylate API Product Portfolio
  84. 4.14.5 Hetero Labs Ltd Recent Developments
  85. 4.15 Dr. Reddy’s
  86. 4.15.1 Dr. Reddy’s Company Information
  87. 4.15.2 Dr. Reddy’s Business Overview
  88. 4.15.3 Dr. Reddy’s Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Dr. Reddy’s Imatinib Mesylate API Product Portfolio
  90. 4.15.5 Dr. Reddy’s Recent Developments
  91. 4.16 Cipla Ltd
  92. 4.16.1 Cipla Ltd Company Information
  93. 4.16.2 Cipla Ltd Business Overview
  94. 4.16.3 Cipla Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Cipla Ltd Imatinib Mesylate API Product Portfolio
  96. 4.16.5 Cipla Ltd Recent Developments
  97. 4.17 Aurobindo Pharma Ltd
  98. 4.17.1 Aurobindo Pharma Ltd Company Information
  99. 4.17.2 Aurobindo Pharma Ltd Business Overview
  100. 4.17.3 Aurobindo Pharma Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Aurobindo Pharma Ltd Imatinib Mesylate API Product Portfolio
  102. 4.17.5 Aurobindo Pharma Ltd Recent Developments
  103. 4.18 Acebright India Pharma Private Ltd
  104. 4.18.1 Acebright India Pharma Private Ltd Company Information
  105. 4.18.2 Acebright India Pharma Private Ltd Business Overview
  106. 4.18.3 Acebright India Pharma Private Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Acebright India Pharma Private Ltd Imatinib Mesylate API Product Portfolio
  108. 4.18.5 Acebright India Pharma Private Ltd Recent Developments
5 Global Imatinib Mesylate API Market Scenario by Region
  1. 5.1 Global Imatinib Mesylate API Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Imatinib Mesylate API Sales by Region: 2021-2032
  3. 5.2.1 Global Imatinib Mesylate API Sales by Region: 2021-2026
  4. 5.2.2 Global Imatinib Mesylate API Sales by Region: 2027-2032
  5. 5.3 Global Imatinib Mesylate API Revenue by Region: 2021-2032
  6. 5.3.1 Global Imatinib Mesylate API Revenue by Region: 2021-2026
  7. 5.3.2 Global Imatinib Mesylate API Revenue by Region: 2027-2032
  8. 5.4 North America Imatinib Mesylate API Market Facts & Figures by Country
  9. 5.4.1 North America Imatinib Mesylate API Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Imatinib Mesylate API Sales by Country (2021-2032)
  11. 5.4.3 North America Imatinib Mesylate API Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Imatinib Mesylate API Market Facts & Figures by Country
  16. 5.5.1 Europe Imatinib Mesylate API Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Imatinib Mesylate API Sales by Country (2021-2032)
  18. 5.5.3 Europe Imatinib Mesylate API Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Imatinib Mesylate API Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Imatinib Mesylate API Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Imatinib Mesylate API Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Imatinib Mesylate API Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Imatinib Mesylate API Market Facts & Figures by Country
  41. 5.7.1 South America Imatinib Mesylate API Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Imatinib Mesylate API Sales by Country (2021-2032)
  43. 5.7.3 South America Imatinib Mesylate API Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Imatinib Mesylate API Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Imatinib Mesylate API Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Imatinib Mesylate API Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Imatinib Mesylate API Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Imatinib Mesylate API Sales by Type (2021-2032)
  2. 6.1.1 Global Imatinib Mesylate API Sales by Type (2021-2032) & (kg)
  3. 6.1.2 Global Imatinib Mesylate API Sales Market Share by Type (2021-2032)
  4. 6.2 Global Imatinib Mesylate API Revenue by Type (2021-2032)
  5. 6.2.1 Global Imatinib Mesylate API Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Imatinib Mesylate API Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Imatinib Mesylate API Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Imatinib Mesylate API Sales by Application (2021-2032)
  2. 7.1.1 Global Imatinib Mesylate API Sales by Application (2021-2032) & (kg)
  3. 7.1.2 Global Imatinib Mesylate API Sales Market Share by Application (2021-2032)
  4. 7.2 Global Imatinib Mesylate API Revenue by Application (2021-2032)
  5. 7.2.1 Global Imatinib Mesylate API Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Imatinib Mesylate API Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Imatinib Mesylate API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Imatinib Mesylate API Value Chain Analysis
  2. 8.1.1 Imatinib Mesylate API Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Imatinib Mesylate API Production Mode & Process
  5. 8.2 Imatinib Mesylate API Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Imatinib Mesylate API Distributors
  8. 8.2.3 Imatinib Mesylate API Customers
9 Global Imatinib Mesylate API Analyzing Market Dynamics
  1. 9.1 Imatinib Mesylate API Industry Trends
  2. 9.2 Imatinib Mesylate API Industry Drivers
  3. 9.3 Imatinib Mesylate API Industry Opportunities and Challenges
  4. 9.4 Imatinib Mesylate API Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst